{"organizations": [], "uuid": "33a55da079110ae45f350d78def5db0f075d2282", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-acorda-announces-fda-acceptance-of/brief-acorda-announces-fda-acceptance-of-new-drug-application-for-inbrija-idUSASB0C6B3", "country": "US", "domain_rank": 408, "title": "BRIEF-Acorda Announces FDA Acceptance Of New Drug Application For Inbrija", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.957, "site_type": "news", "published": "2018-02-20T19:13:00.000+02:00", "replies_count": 0, "uuid": "33a55da079110ae45f350d78def5db0f075d2282"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-acorda-announces-fda-acceptance-of/brief-acorda-announces-fda-acceptance-of-new-drug-application-for-inbrija-idUSASB0C6B3", "ord_in_thread": 0, "title": "BRIEF-Acorda Announces FDA Acceptance Of New Drug Application For Inbrija", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "acorda therapeutics inc", "sentiment": "negative"}, {"name": "fda acceptance of new drug application for inbrija", "sentiment": "negative"}, {"name": "acorda", "sentiment": "negative"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Acorda Therapeutics Inc:\n* ACORDA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR INBRIJAâ„¢ (LEVODOPA INHALATION POWDER)\n* ACORDA THERAPEUTICS INC - UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA), FDA HAS SET A TARGET DATE OF OCTOBER 5, 2018 FOR INBRIJA Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T19:13:00.000+02:00", "crawled": "2018-02-21T21:40:36.012+02:00", "highlightTitle": ""}